Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: phenylacetate Clear all
Terminated Phase 4 Interventional Results available

Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis

NCT03473665
View directory record Official record
Conditions
Ankylosing Spondylitis, Axial Spondyloarthritis
Interventions
Indomethacin, Diclofenac, Meloxicam, Celecoxib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 4 Interventional

Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder

NCT00181987
View directory record Official record
Conditions
ADHD, Bipolar Disorder
Interventions
methylphenidate HCl (Concerta)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 4 Interventional

A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder

NCT00181571
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate HCl (Concerta), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Guanfacine to Improve Substance Use Outcomes in Women

NCT03980184
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Guanfacine, Behavioral Counseling
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 22, 2026, 2:07 AM EDT
Not yet recruiting Early Phase 1 Interventional

Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial

NCT07757555
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome (POTS), Dysautonomia, Orthostatic Intolerance, Autonomic Nervous System Diseases
Interventions
Guanfacine (GFC), Cromolyn Sodium, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

NCT04085172
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute

NCT01982539
View directory record Official record
Conditions
Pain
Interventions
Zipsor®
Drug
Lead sponsor
Depomed
Industry
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Sheffield, Alabama • Stanford, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 3 Interventional

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

NCT00389779
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
87
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 1 Interventional

Guanfacine to Reduce Stress-Induced Cocaine/Alcohol Craving and Relapse

NCT00585754
View directory record Official record
Conditions
Cocaine Dependent, Alcohol Dependent
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study

NCT00495820
View directory record Official record
Conditions
Alzheimer's Disease, Apathy, Dementia
Interventions
Methylphenidate, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.

NCT03811847
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Methylphenidate Extended Release Oral Capsule, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 95 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

NCT01069523
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine Extended Release, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
6 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Discriminative Effects of Tramadol in Humans

NCT00499746
View directory record Official record
Conditions
Opioid Abuse, Opioid Addiction, Stimulant Abuse, Stimulant Addiction
Interventions
tramadol, placebo, Hydromorphone, Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Months to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers

NCT01202734
View directory record Official record
Conditions
Healthy
Interventions
Methylphenidate HCl
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
20 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Study of Medication Patch to Treat Children Ages 6-12 With ADHD

NCT00586157
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Sep 22, 2026, 2:07 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin

NCT00276419
View directory record Official record
Conditions
Breast Pain, Non-cyclical Mastalgia, Surgical Scar-Related Breast Pain
Interventions
Diclofenac, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Sep 22, 2026, 2:07 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT01156051
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
Interventions
Guanfacine extended-release tablets, Placebo comparator
Drug
Lead sponsor
Children's Specialized Hospital
Other
Eligibility
6 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Hamilton, New Jersey • Toms River, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 10, 2014 · Synced Sep 22, 2026, 2:07 AM EDT
Completed No phase listed Observational

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).

NCT02141113
View directory record Official record
Conditions
Adult Attention-Deficit Hyperactivity Disorder
Interventions
Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 2Phase 3 Interventional

OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD

NCT02215538
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OROS methylphenidate, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Omega-3 Supplementation to ADHD Medication in Children

NCT02204410
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Interventions
Omega-3 Fatty Acid, ADHD Medication
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety

NCT02021214
View directory record Official record
Conditions
PTSD
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 22, 2026, 2:07 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

NCT00922636
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LY2216684, Methylphenidate, Placebo (tablet), Placebo (capsule)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Spring Valley, California • Bradenton, Florida • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 22, 2026, 2:07 AM EDT